Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (The GOAT Trial) (The GOAT Trial)
Rochester, Minn.
The purpose of this study is to determine whether optimal approach for the management of gram-negative bloodstream-infections (GN-BSI) is (1) intravenous antibiotics for the duration of treatment or (2) initial IV antibiotics followed by early transition to oral antibiotics, accounting for comprehensive patient-informed benefits, adverse events, and quality of life measures through the use of desirability of outcomes rankings and response adjusted for duration of antibiotic risk analytics approach.
Closed for Enrollment
-
A Multicenter, Randomized, Double-blind, Active Controlled Phase I/II Study to Evaluate the Safety, Tolerability, and Potential Efficacy of a Bacteriophage-Loaded Microcapsule Spray (BACTELIDETM) vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for S. aureus, P. aeruginosa, and K. pneumoniae-Colonized Pressure Injuries in Adult Patients (Phagelux Bactelide)
Rochester, Minn.,
Eau Claire, Wis.
The purpose of this study is to evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species. This study will compare the safety and effectiveness of BACTELIDE in conjunction with standard of care (SOC) versus a placebo in conjunction with standard of care.
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of APT Phage Bank Phage Therapy versus Placebo in Conjunction with Debridement, Antibiotics, and Implant Retention (DAIR) in Subjects with Chronic Prosthetic Joint Infection (PJI) (ACTIVE2)
Rochester, Minn.
The purpose of this study is to evaluate bacteriophage therapy + DAIR in patients with chronic prosthetic joint infections.
-
Mayo Clinic Phage Program Biobank (Phagebank)
Rochester, Minn.
The purpose of the bacteriophage registry and biorepository is to centralize collections of human blood from Mayo Clinic patients receiving phage therapy. Laboratory testing from this study will be paired along with clinically significant data including medical history, bacterial infection types, inflammatory biomarkers, antibiotic resistance, and others. We believe that this registry and biorepository of samples will help scientists and clinicians discover answers to research questions related to antibiotic-resistant bacterial infections, and the role that phage therapy plays as a possible treatment.
.